Piramal Enterprises’ Hemmo Pharma Acquisition To Step Up Peptide Skills In CDMO Segment: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Hemmo Pharmaceuticals’ acquisition by Piramal Pharma would add the capability to develop and manufacture complex peptide active pharmaceutical ingredients to the latter’s portfolio.
It further complements services such as drug discovery solutions, process development services, clinical trial-to-commercial supplies of APIs, and formulations.
The valuation of six times enterprise value/FY21 sales (estimated at Rs 1.2 billion) is attractive as it is at a ~50% discount to leading contract development and manufacturing company players such as Divi’s Laboratories Ltd.
We raise the pharma segment Ebitda of Piramal Enterprises Ltd. by 5%/6% for FY22/FY23E after factoring in the acquisition.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.